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Letters to the Editor
try methodology that they used to measure 25(OH)D. This assay
does not distinguish between 25(OH)D and an epimer of 25(OH)D
that is present in variable amounts in most adults, with levels of
the epimer exceeding 7.5 nmol/L in 8% of the adults in one large
study [10]. The epimer binds to the vitamin D receptor, but it
lacks many of the activities of vitamin D [10], so it is likely that
the epimer acts as a competitive inhibitor for some of the activ-
ities of vitamin D. Therefore, the differences in the relationship
between the measured 25(OH)D level [i.e., 25(OH)D plus epimer]
and the actual 25(OH)D level could have compromised the con-
clusions of their study. In contrast, most of the studies, in which
a correlation between 25(OH)D level and the rate of SVR was
identiﬁed, used a 25(OH)D assay that is unaffected by the epimer
[4–7,10].
Considering the variation in vitamin D physiology between
patients and the complexity of measuring vitamin D levels, a lack
of a correlation between 25(OH)D level and the rate of SVR
among a group of patients should not be interpreted as a lack
of importance of vitamin D status in genotype 1 chronic hepatitis
C treatment outcome. In the context of the evidence that vitamin
D has a functional role as a determinant treatment response [8], it
is important to consider the possibility that the level of 25(OH)D
may be important in the response to treatment of an individual
genotype 1 chronic hepatitis C patient, but that this may not be
apparent when the relationship between 25(OH)D level and the
rate of attaining an SVR is analyzed among a group of patients.Conﬂict of interest
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We thank Dr. Weintraub for his in-depth analysis of our paper
and the insightful questions he has raised. Our study of 274
patients showing no independent association between baseline
25-hydroxyvitamin D [25(OH)D] status and sustained virologic
response (SVR) in chronic hepatitis C genotype 1 (HCV-1) infec-
tion [1] was similar to 3 other published studies [2–4] involving
765 patients with HCV-1. Notably, published studies with the
contrary ﬁnding of an association between baseline 25(OH)D
level and SVR in HCV-1 have involved only 448 patients in total,
with the largest including 171 patients.
Ethnic variation is one potential explanation for the differ-
ences observed between studies to date. However, in a further
analysis of the sub-cohort of 234 Caucasian patients in our study,
we found the results of multivariate analysis did not change.
Moreover, the univariate association found between lower
25(OH)D level and SVR in the entire cohort lost statistical signif-
icance. This is not surprising as the Asian population (n = 34) in
our study had a lower 25(OH)D level but a higher prevalence of
rs12979860 interleukin-28B (IL28B) CC genotype. Indeed, our
study found a trend association between IL28B CC genotype and
lower 25(OH)D level.
Our study only comments on baseline 25(OH)D status and
SVR and does not address whether the in vitro antiviral effect of
vitamin D in HCV infection translates to improved treatment out-
comes to PegIFN-based antiviral therapy in HCV-1. This question
is best addressed by a randomized, placebo-controlled clinical
trial. Unfortunately, this data is lacking and the few prospective
studies on vitamin D supplementation are small and do not
involve a placebo-control arm [5,6]. Any further studies address-194 Journal of Hepatology 2013 vol. 59 j 190–199
ing the issue of vitamin D supplementation on SVR in HCV-1
should, however, include evaluation of genetic polymorphisms
in vitamin D synthesis and metabolism, given the potential inﬂu-
ence of these factors on the results as detailed below.
The synthesis and metabolism of vitamin D is a complex and
tightly regulated process, and there are many genetic and envi-
ronmental determinants of vitamin D status. Genetic polymor-
phisms in key proteins such as vitamin D-binding protein [7]
and 1a-hydroxylase [2,3] have been shown to inﬂuence SVR to
PegIFN-based antiviral therapy in HCV-1 infection. Vitamin D-
binding protein is highly polymorphic with extensive racial vari-
ation, and different isoforms have variable afﬁnity for vitamin D
metabolites. Furthermore, it has anti-inﬂammatory and immuno-
modulatory properties independent of its role as the main carrier
protein for 25(OH)D and 1a,25-dihydroxyvitamin D
[1a,25(OH)2D] [8]. 1a,25(OH)2D is the biologically active product
of 1a-hydroxylase and ligand of the nuclear vitamin D receptor. It
is intuitive that genetic polymorphisms in 1 a-hydroxylase inﬂu-
ence downstream gene transcription of the >200 vitamin D target
genes. Measurement of 25(OH)D level is a poor surrogate for
measurement of 1a,25(OH)2D level or genetic variation in
vitamin D-binding protein and 1a-hydroxylase. We believe that
further studies of genetic polymorphisms in these two genes
are warranted, however, much like IL28B polymorphisms, the
inﬂuence of any genetic variation on SVR in HCV-1 infection is
likely to be attenuated in the direct-acting antiviral era [9].
With regards to the accuracy of the 25(OH)D assay used in our
study, we agree that the interference of C-3 epimers can lead to
overestimation of 25(OH)D level when liquid chromatography-
tandem mass spectrometry (LC-MS/MS) methodology is used.
However, samples were tested in a laboratory using LC-MS/MS
methodology calibrated against the National Institute of Stan-
dards and Technology standard reference material for 25(OH)D
assays. In this particular laboratory, adult C-3 epimer concentra-
tions are <5 nmol/L, thus minimizing any 25(OH)D overestima-
tion bias in our study. Furthermore, every other commercially
available 25(OH)D assay has signiﬁcant limitations in accuracy,
which is why LC-MS/MS methodology currently remains the ref-
erence standard [10].
The results of our negative study appear to raise more ques-
tions than it answers and, much like the synthesis and metabo-
lism of vitamin D, any relationship vitamin D status has with
HCV-1 treatment outcome is likely to be complex.
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